论文部分内容阅读
Eltrombopag(商品名为PROMACTA)是一种血小板生成素(thrombopoietin,TPO)受体激动剂,由葛兰素史克公司研发,2008年11月20日获美国FDA批准上市,用于
Eltrombopag (trade name PROMACTA) is a thrombopoietin (TPO) receptor agonist developed by GlaxoSmithKline and approved by the U.S. FDA on November 20, 2008 for use in